Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
-$0.26 today
- Market cap
- $618.50M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
Volume 1.18M
Average 1.27M
OLMA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Olema Pharmaceuticals, Inc.NASDAQ: OLMA
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.52, compared with -$0.36 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.02.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$2.22 (-18.7%) for the fiscal year ending Dec 2026, a slowdown from the +15.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.52-4.0% QoQ
- Last fiscal yearDec 2025
- -$1.87+15.0% YoY
- LTMMar 2026
- -$2.02+2.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.4% | -8.3% | +36.2 pp |
| 1 year | +15.0% | -18.7% | -33.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.87) USD
- Year-over-year change
- +15.0%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.87) | +15.0% |
| FY2024 | 2024-12-31 | (2.20) | -2.8% |
| FY2023 | 2023-12-31 | (2.14) | +18.3% |
| FY2022 | 2022-12-31 | (2.62) | -46.4% |
| FY2021 | 2021-12-31 | (1.79) | — |
EPS (Basic) vs competitors
How OLMA compares with its peers on the latest reported figures
- OLMA's LTM Mar 2026 EPS (Basic) of -$2.02 is the lowest of the 2 companies compared; the peer median is $0.5.
- Its year-over-year change of +2.4% is the highest of 2, against a peer median of -35.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.5 | -35.2% | +212.1% | |
| LTM Mar 2026 | -$2.02 | +2.4% | — | |
| Peer median (excluding OLMA) | $0.5 | -35.2% | +212.1% | |
Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 51.1M | 82.27M | 86.14M | 124.52M | 157.7M |
| Selling, General & Admin | 20.39M | 24.71M | 18.82M | 17.74M | 21M |
| Operating Expenses | 71.49M | 106.99M | 104.96M | 142.26M | 178.7M |
| Depreciation & Amortization | 163K | 357K | 377K | 393K | 490K |
| EBITDA | (70.93M) | (104.43M) | (96.28M) | (129.08M) | (161.96M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (71.49M) | (106.99M) | (104.96M) | (142.26M) | (178.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 442K | 2.23M | 8.32M | 12.68M | 16.22M |
| Interest Expense | — | 0 | — | 0 | 0 |
| Other Income / Expenses | 395K | 2.2M | 8.31M | 12.78M | 16.25M |
| Income Before Tax | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.62) | (2.14) | (2.20) | (1.87) |
| EPS (Diluted) | (1.79) | (2.62) | (2.14) | (2.20) | (1.87) |
| Weighted Avg Shares | 39.52M | 40M | 45.25M | 58.74M | 87.01M |
| Weighted Avg Shares (Diluted) | 39.52M | 40M | 45.25M | 58.74M | 87.01M |
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
Intrinsic Alpha fair value
Locked
Current Price
$7.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.